ATOSIBAN
Atropine is an anticholinergic agent blocking muscarinic receptors, reducing secretions and increasing heart rate. It is used in bradycardia, organophosphate poisoning, and preoperative settings. Benefits include rapid onset and strong parasympathetic inhibition. Side effects include dry mouth, blurred vision, urinary retention, tachycardia, and confusionespecially in elderly patients. Only GMP materials will be supplied, logistics all according to GDP.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of action
Atosiban is a synthetic peptide antagonist of the oxytocin receptor (OXTR) and, to a lesser extent, vasopressin VA receptors. It competitively inhibits oxytocin binding on uterine smooth muscle, thereby reducing inositol trisphosphate (IP)-mediated calcium release from intracellular stores and decreasing myometrial contractility. This results in dose-dependent tocolysis without the -adrenergic stimulation associated with other tocolytic agents.
Benefits and advantages
Atosiban is highly relevant in obstetric pharmacology for investigating uterine contractility, receptor-mediated calcium signalling, preterm labour models and peptide receptor pharmacodynamics. Its selectivity for OXTR allows mechanistic studies that distinguish oxytocin-driven contractions from other uterotonic pathways.
Side effects and risks
Potential adverse effects observed clinically include hypotension, nausea, headache, injection-site reactions and transient changes in foetal heart rate. As a peptide drug substance, atosiban must be manufactured and handled under peptide-grade conditions, with attention to temperature, oxidation and peptide aggregation.
Only GMP materials will be supplied, logistics all according to GDP.
Datasheet
| Molecular Formula | C43H67N11O12S2 |
|---|---|
| Molecular Weight | 994.2 g/mol |
| CAS Number | 90779-69-4 |
| Storage Condition | Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light. |
| Solubility | Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance. |
| Purity | Purity information is available upon request (COA). |
| Synonym | Atosiban; 90779-69-4; Tractocile; Antocin; Antocin II |
| IUPAC/Chemical Name | (2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16R)-7-(2-amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide |
| InChl Key | VWXRQYYUEIYXCZ-OBIMUBPZSA-N |
| InChl Code | InChI=1S/C43H67N11O12S2/c1-5-23(3)35-41(63)53-36(24(4)55)42(64)50-29(20-32(45)56)38(60)51-30(43(65)54-17-8-10-31(54)40(62)49-27(9-7-16-44)37(59)47-21-33(46)57)22-68-67-18-15-34(58)48-28(39(61)52-35)19-25-11-13-26(14-12-25)66-6-2/h11-14,23-24,27-31,35-36,55H,5-10,15-22,44H2,1-4H3,(H2,45,56)(H2,46,57)(H,47,59)(H,48,58)(H,49,62)(H,50,64)(H,51,60)(H,52,61)(H,53,63)/t23-,24+,27-,28+,29-,30-,31-,35-,36-/m0/s1 |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
